Sigma-Aldrich Co. has announced a licensing deal with NeuroSurvival Technologies Ltd. by which Sigma-Aldrich will be allowed to market and manufacture a marker that can detect apoptosis in vitro and in vivo. The marker, commercially known as Apo-TRACE, is one of a number of small molecules, referred to collectively as ApoSense™, that NeuroSurvival has developed to detect apoptotic cells in vivo. An overview of NeuroSurvival's ApoSense™ technology is available here. The markers can be used for molecular imaging in the areas of disease staging/diagnosis, treatment monitoring, and drug development.
ApoSense™ Positron Emission Tomography (PET) scans can be viewed here.
Jason Derry, Ph.D., who graduated with honors from DePaul University College of Law, is a molecular biologist and founding author of Patent Docs.
Comments